Eric L Sievers
Overview
Explore the profile of Eric L Sievers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
3586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Duvic M, Reddy S, Pinter-Brown L, Korman N, Zic J, Kennedy D, et al.
Clin Cancer Res
. 2009 Oct;
15(19):6217-24.
PMID: 19789316
Purpose: An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30(+) primary cutaneous anaplastic large cell...
22.
Raza A, Jurcic J, Roboz G, Maris M, Stephenson J, Wood B, et al.
Leuk Lymphoma
. 2009 Jun;
50(8):1336-44.
PMID: 19557623
A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies. In this study, higher doses than previously tested and...
23.
Forero-Torres A, Leonard J, Younes A, Rosenblatt J, Brice P, Bartlett N, et al.
Br J Haematol
. 2009 May;
146(2):171-9.
PMID: 19466965
SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open-label, Phase II study...
24.
Oflazoglu E, Kissler K, Sievers E, Grewal I, Gerber H
Br J Haematol
. 2008 May;
142(1):69-73.
PMID: 18477046
The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of...
25.
Aplenc R, Alonzo T, Gerbing R, Lange B, Hurwitz C, Wells R, et al.
J Clin Oncol
. 2008 May;
26(14):2390-3295.
PMID: 18467731
Purpose: While gemtuzumab ozogamicin (GTMZ) is commonly used in the treatment of acute myeloid leukemia (AML) in combination with standard chemotherapy agents, the pediatric maximum-tolerated dose (MTD) of GMTZ in...
26.
Thompson J, Curti B, Redman B, Bhatia S, Weber J, Agarwala S, et al.
J Clin Oncol
. 2008 Mar;
26(12):2034-9.
PMID: 18347008
Purpose: A phase I study of patients with metastatic malignant melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor...
27.
Larson R, Sievers E, Stadtmauer E, Lowenberg B, Estey E, Dombret H, et al.
Cancer
. 2005 Aug;
104(7):1442-52.
PMID: 16116598
Background: In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). Methods: Patients with CD33-positive AML...
28.
Arceci R, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, et al.
Blood
. 2005 May;
106(4):1183-8.
PMID: 15886328
This open-label, dose-escalation study evaluated the safety and efficacy of single-agent gemtuzumab ozogamicin, a humanized anti-CD33 antibody-targeted chemotherapeutic agent, for pediatric patients with multiple relapsed or primary refractory acute myeloid...
29.
30.
Aplenc R, Vachani A, Han P, Glatfelter W, Sievers E
Acta Haematol
. 2003 Dec;
110(4):207-10.
PMID: 14663169
No abstract available.